Navigation Links
Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
Date:11/30/2011

CORAL SPRINGS, Fla., Nov. 30, 2011 /PRNewswire/ -- Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the journal Neuropharmacology will be publishing a mechanism study on the use of Alpha-Cobratoxin, a component of cobra venom, as a treatment for pain. The paper was co-authored by Paul Reid, PhD - the Chief Executive Officer of Nutra Pharma's wholly-owned subsidiary, ReceptoPharm and is available ahead of print on the journal's website or through the link: http://tinyurl.com/painmechanism.

"We are pleased to see continuing publications on the uses of cobra venom and cobra venom components," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "This paper explains one of the proposed mechanisms involved in the relief of pain that we've seen with our venom-based therapeutics, Cobroxin and Nyloxin," he concluded.

Nutra Pharma currently produces three drugs for the treatment of pain: Cobroxin®, an over-the-counter pain reliever designed to treat moderate to severe (Stage 2) chronic pain; as well as Nyloxin™ and Nyloxin™ Extra Strength, stronger versions of Cobroxin®. These products are currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress.

"Most of the published research conducted on the use of cobra venom as an analgesic took place decades ago," commented Dr. Paul Reid, CEO of ReceptoPharm. "We have been working diligently to bring the research up to date. While it is well-known that peptides from cobra venom could be used for the treatment of pain and inflammation, the mechanism has not been well-defined. The research in this paper provides a growing understanding of the mechanism of action in pain relief by Alpha-Cobratoxin," he concluded.

About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The publication of this article should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.  Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


'/>"/>
SOURCE Nutra Pharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Nutra Pharma CEO Interviewed by Wall Street Reporter
2. Functional Nutriments Awarded Federal Grant to Apply Its Dog Nutraceutical Research to Human Cancer
3. Nutrastar International Inc. Announces Record Second Quarter 2010 Results
4. Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing
5. 2nd Algae World Europe Tracks Algae Commercialization from Algae Production to High-value Products- Nutraceuticals, Aquaculture Feed, Cosmetics, Biofuels and More
6. Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products
7. WellGen Recognized as Nutraceutical “Innovator” by Global Business Insights
8. Henk Hoogenkamp, Accomplished Author and Food Ingredient Scientist, Joins NutraCea as Executive Advisor on the Utilization of Stabilized Rice Bran in Food Ingredient Applications
9. Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health
10. Reuters Highlights NutraPharma Financial Giant Predicts NutraPharma (OTCBB: NPHC) Shares Likely to Outperform the Market
11. Nutra Pharmaceutical's U.S. distributor, XenaCare Holdings Announces National Print Advertising Campaign for Cobroxin, a Treatment for Moderate to Severe (Stage 2) Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. ... STACS DNA as a Field Application Specialist. , “I am thrilled that Dr. ... STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings a ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
Breaking Biology News(10 mins):